Evgen Pharma PLC Result of General Meeting & Total Voting Rights (0583R)
03 March 2021 - 11:10PM
UK Regulatory
TIDMEVG
RNS Number : 0583R
Evgen Pharma PLC
03 March 2021
Evgen Pharma plc
("Evgen" or "the Company")
Result of General Meeting
and
Total Voting Rights
Evgen Pharma plc (AIM: EVG), the clinical stage drug development
company developing sulforaphane based medicines for the treatment
of multiple diseases, announces that at the General Meeting held
earlier today, the Resolutions proposed were duly passed by
shareholders on a poll.
The numbers of votes cast for and against each of the
Resolutions are detailed below:
Resolution Votes for % of votes cast Votes against % of votes cast Total votes cast Votes withheld
1 34,363,025 99.91% 30,000 0.09% 34,393,025 108,375
----------- ---------------- -------------- ---------------- ----------------- ---------------
2 34,324,025 99.82% 61,695 0.18% 34,385,720 115,680
----------- ---------------- -------------- ---------------- ----------------- ---------------
It is expected that the Admission of the Placing Shares and the
Open Offer shares will become effective at 8:00 a.m. on 4 March
2021.
Following Admission, the Company will have in issue 274,888,117
Ordinary Shares, with no shares held in treasury. Shareholders may
use this figure as the denominator by which they are required to
notify their interest in, or change to their interest in, the
Company under the Disclosure Guidance and Transparency Rules.
Unless otherwise defined, terms in this announcement shall have
the same meanings as those defined in the Placing and Open Offer
announcement issued on 2 February 2021.
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
--------------------------------------
Dr H uw Jones CEO
--------------------------------------
Richard Moulson, CFO
--------------------------------------
finnCap www.finncap.com +44 (0) 20 7220 0500
--------------------------------------
Geoff Nash / Teddy Whiley (Corporate
Finance)
--------------------------------------
Alice Lane, Manasa Patil (ECM)
--------------------------------------
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
--------------------------------------
+44 (0)7980 541 893 / +44 (0)7876 741
Paul McManus / Anna Dunphy 001
--------------------------------------
About Evgen Pharma plc
Evgen Pharma is a clinical stage company developing sulforaphane
based medicines for the treatment of multiple diseases The
Company's core technology is Sulforadex (R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. Our lead
product, SFX-01, has demonstrated efficacy in a Phase II trial for
advanced metastatic breast cancer. It has been used to treat over
150 patients in clinical trials and is well-tolerated with
predominately mild side-effects.
Evgen shares are traded on the AIM market of the London Stock
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
Accordingly, the Company makes the following announcement and
notification in accordance with the EU Market Abuse Regulation (No
596/2014):
1. Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated
with them ('PCA')
=== ================================================================================================
a) Name Huw Jones
=== ============================================ ==================================================
2. Reason for notification
=== ================================================================================================
b) Position / status CEO
=== ============================================ ==================================================
c) Initial notification / amendment Initial Notification
=== ============================================ ==================================================
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
=== ================================================================================================
b) Name Evgen Pharma plc
=== ============================================ ==================================================
c) LEI 213800NO3E6TSTQO8K20
=== ============================================ ==================================================
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
=== ================================================================================================
a) Description of the financial instrument ordinary shares of 0.25p each
Identification code
GB00BSVYN304
=== ============================================ ==================================================
b) Nature of the transaction Acquisition of shares pursuant to the Placing
=== ============================================ ==================================================
c) Price(s) and volume(s) Price(s) Volume(s)
GBP0.08 62,500
----------
=== ============================================ ==================================================
d) Aggregated information As above
Aggregated volume Price
=== ============================================ ==================================================
e) Date of the transaction 3 March 2021
=== ============================================ ==================================================
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
=== ============================================ ==================================================
1. Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated
with them ('PCA')
=== ================================================================================================
a) Name Sue Foden
=== ============================================ ==================================================
2. Reason for notification
=== ================================================================================================
b) Position / status Non-Executive Director
=== ============================================ ==================================================
c) Initial notification / amendment Initial Notification
=== ============================================ ==================================================
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
=== ================================================================================================
b) Name Evgen Pharma plc
=== ============================================ ==================================================
c) LEI 213800NO3E6TSTQO8K20
=== ============================================ ==================================================
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
=== ================================================================================================
a) Description of the financial instrument Ordinary Shares of 0.25p each
Identification code
GB00BSVYN304
=== ============================================ ==================================================
b) Nature of the transaction Acquisition of shares pursuant to the Placing
=== ============================================ ==================================================
c) Price(s) and volume(s) Price(s) Volume(s)
GBP0.08 125,000
----------
=== ============================================ ==================================================
d) Aggregated information As above
Aggregated volume Price
=== ============================================ ==================================================
e) Date of the transaction 3 March 2021
=== ============================================ ==================================================
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
=== ============================================ ==================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMSSAFEDEFSESD
(END) Dow Jones Newswires
March 03, 2021 07:10 ET (12:10 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024